Patents Examined by James D. Anderson
  • Patent number: 10328048
    Abstract: A method is provided of treating, preventing or ameliorating type 2 diabetes and/or a clinical condition associated with type 2 diabetes, which method comprises administering an effective amount of cafestol or a derivative thereof including esters and salts thereof to a person in need thereof. Further provided are compositions comprising cafestol and at least one additional agent suitable for treating, preventing or ameliorating diabetes and/or a clinical condition associated with diabetes. A method is also provided of increasing insulin secretion and/or increasing insulin-dependent glucose uptake, said method comprising administering an effective amount of cafestol or a derivative thereof to a person in need thereof.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: June 25, 2019
    Assignees: Aarhus Universitet, Region Midtjylland
    Inventors: Søren Gregersen, Per Bendix Jeppesen, Kjeld Hermansen, Fredrik Brustad Mellbye
  • Patent number: 10328088
    Abstract: A method for the treatment or prophylaxis of non-inflammatory bowel diseases, diarrhoea-predominant irritable bowel syndrome or other non-specific bowel disorder is disclosed comprising administering to a patient in need of such treatment or prophylaxis an effective amount of balsalazide, or a 4-ASA or 5-ASA compound modified to include a 4-ABA side chain, or a salt or a derivative thereof, or a composition comprising balsalazide the modified compound, or a salt or a derivative thereof together with a suitable carrier. Use of balsalazide, a 4-ASA or 5-ASA compound modified to include a 4-ABA side chain, or a salt or derivative thereof, for the manufacture of a medicament for the treatment or prophylaxis of non-inflammatory bowel diseases, diarrhoea-pre-dominant Irritable Bowel Syndrome or other non-specific bowel disorder is also disclosed.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: June 25, 2019
    Assignee: Salix Pharmaceuticals, Inc.
    Inventor: Nicolas Peter Shortis
  • Patent number: 10328069
    Abstract: Methods are provided for treating a lymphoproliferative malignancy to a patient in need of such treatment, comprising administering to the patient an effective amount of compound A as described herein.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: June 25, 2019
    Assignee: EXELIXIS, INC.
    Inventors: Arthur DeCillis, Joanne Lager
  • Patent number: 10322125
    Abstract: This disclosure relates to compounds and compositions for cartilage repair and methods related thereto. In certain embodiments, the disclosure relates to methods of inducing cartilage growth and regeneration comprising administering an effective amount of a composition comprising a compound disclosed herein to the subject or implanting a cartilage matrix comprising a compound disclosed herein in the subject. In certain embodiments, the compound is used locally such as injection at any desired site of cartilage formation.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: June 18, 2019
    Assignees: Emory University, The United States of America as represented by the Department of Veteran Affairs
    Inventors: Scott D Boden, Sreedhara Sangadala
  • Patent number: 10314323
    Abstract: The present invention involves methods for improving the quality of the hair of a non-human animal and for increasing the 18-methyleicosanoic acid content of the hair of a non-human animal comprising feeding to the animal an edible composition comprising an effective amount of an amino acid selected from the group comprising isoleucine, threonine, and mixtures thereof.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: June 11, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Shiguang Yu, Joseph Greitl
  • Patent number: 10300015
    Abstract: The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: May 28, 2019
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Viviane Bertrand
  • Patent number: 10301307
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: May 28, 2019
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Takeru Furuya
  • Patent number: 10300071
    Abstract: A composition comprising a drug selected from the group consisting of an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, a substituted quinol, or a salt, hydrate, or prodrugs thereof, or a combination thereof, in an amount and formulation sufficient to inhibit a mycobacterium is disclosed.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: May 28, 2019
    Assignee: The Texas A&M University System
    Inventors: Manchi C M Reddy, James C. Sacchettini, Nian E. Zhou, Billy F. McCutchen
  • Patent number: 10294231
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: May 21, 2019
    Assignee: Pharmacyclics LLC
    Inventors: Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
  • Patent number: 10294232
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: May 21, 2019
    Assignee: Pharmacyclics LLC
    Inventors: Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
  • Patent number: 10278940
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 7, 2019
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Patent number: 10272096
    Abstract: The invention generally relates to methods for treating and/or reducing the severity of a wound in a subject. Provided are wound therapies combining low level light therapy (LLLT) and a nitric oxide (NO) donor to treat and/or reduce the severity of the wound. The LLLT and NO donor may be administered concurrently or sequentially. Also provided are wound treatment systems and kits including a light source and a NO donor, which are administered to a wounded subject. Further provided are pharmaceutical compositions that comprise a NO donor and are formulated to be administered in conjunction with LLLT.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: April 30, 2019
    Inventors: Michael W. Berns, Ryan M. Spitler, Gerard Boss
  • Patent number: 10251871
    Abstract: Provided are pharmaceutical compositions and methods of treating or preventing edema, using an anti-T cell agent, an anti-TGF-?1 agent, or an anti-angiotensin agent, preferably a combination of at least two such agents. The pharmaceutical compositions can be formulated for systemic or local administration, and are preferably administered topically.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: April 9, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Babak Mehrara, Jason Gardenier, Ira Savetsky, Omer Aras
  • Patent number: 10245257
    Abstract: The present invention provides methods for treating onychomycosis. In certain embodiments, the methods comprise comprising applying a pharmaceutically acceptable formulation containing 10% efinaconazole once a day for a treatment period of at least 36 weeks to the treatment area of an onychomycosis patient (a) without debriding the nail or nail-associated tissue initially or during the treatment period and/or (b) without removing the formulation from the treatment area during the treatment period. In certain embodiments, the formulation also comprises, water, cyclomethicone, diisopropyl adipate, alcohol, C12-15 alkyl lactate, butylated hydroxytoluene, citric acid anhydrous, and disodium edetate.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: April 2, 2019
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Radhakrishnan Pillai, Gordon Dow
  • Patent number: 10245245
    Abstract: Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: April 2, 2019
    Assignee: Vireo Systems, Inc.
    Inventors: Mark C. Faulkner, Donald W. Miller, Grant M. Hatch
  • Patent number: 10240210
    Abstract: Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists. The methods may comprise administering RARA agonists to patient populations.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: March 26, 2019
    Assignee: Syros Pharmaceuticals, Inc.
    Inventors: Michael Robert McKeown, Christopher Fiore, Matthew Lucas Eaton, Emily Payton Lee, Christian Fritz
  • Patent number: 10231961
    Abstract: Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: March 19, 2019
    Assignee: GENUS LIFESCIENCES INC.
    Inventors: Jeffrey M. Moshal, Michael Libman
  • Patent number: 10231927
    Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 19, 2019
    Assignee: Rosemont Pharmaceuticals Ltd.
    Inventors: Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
  • Patent number: 10231959
    Abstract: Disclosed herein are methods for counteracting age-related decrease in gene expression or treating age-related diseases, for example cancers and autoimmune diseases, caused by decreased expression levels of a gene associated with the apoptosis pathway, using a nitroxide. Further disclosed are methods for treating a human subject in need of an increased expression level of a gene associated with the apoptosis pathway using a nitroxide.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: March 19, 2019
    Inventor: Louis Habash
  • Patent number: 10226438
    Abstract: Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: March 12, 2019
    Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Thomas S. Scanlan, Meredith Hartley, Andrew Placzek, Marco Righi, Dennis Bourdette, Gail Marracci, Priya Chaudhary